FINWIRES · TerminalLIVE
FINWIRES

Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says

-- Axsome Therapeutics' (AXSM) shares are likely facing an "attractive setup" ahead of the US Food and Drug Administration's approval decision of a label expansion of Auvelity into Alzheimer's disease agitation, Oppenheimer said in a note Tuesday.

Oppenheimer said it forecasts a 20% upside with a 95% probability versus a 35% downside upon the FDA's decision, reflecting the investment firm's about $2 billion sales estimate, with a priority review for the drug backing its conviction.

The investment firm noted Auvelity was originally approved for major depressive disorder in Q3 2022, and was also given breakthrough therapy designation for a potential label expansion into Alzheimer's disease agitation.

Oppenheimer said it sees "distinct commercial advantages" for Auvelity, as it may "compete on clean safety, which also justifies formulary positioning and longer-term use" compared with competing Alzheimer's disease agitation drug Rexulti.

Meanwhile, Auvelity is also competitively well-positioned compared with candidate drugs in development like Cobenfy, which are "far behind," the note said.

Oppenheimer has an outperform rating on Axsome and a $220 price target.

Price: $183.26, Change: $-5.43, Percent Change: -2.88%

Related Articles

Asia

Bank of Queensland Posts Lower Fiscal H1 Cash Earnings, Higher Revenue

Bank of Queensland (ASX:BOQ) reported Wednesday fiscal first-half cash earnings of AU$0.253 per share, down from AU$0.264 a year earlier.Analysts polled by FactSet expected earnings of AU$0.26.Revenue from ordinary activities for the six months ended Feb. 28 was AU$835 million, compared with AU$802 million a year earlier.Analysts surveyed by FactSet expected AU$839 million.The company has maintained its common equity tier 1 management target range at 10.25% to 10.75%, along with an unchanged dividend payout ratio target of 60% to 75% of cash earnings, while also keeping its cost guidance steady and continuing to expect cost growth from 2025 to 2026 to remain below the rate of inflation.The board declared an interim dividend of AU$0.20 per share, up from AU$0.18 a year earlier, payable May 27 to shareholders on record as of May 5.

$ASX:BOQ
Asia

Carnaby Resources Continues to Be Undervalued Relative to Peers, Euroz Hartleys Says

Carnaby Resources (ASX:CNB) continues to be undervalued relative to its peers and given its production potential, Euroz Hartleys said in a Tuesday note, adding that the market may have missed a near-term production opportunity.The company has commenced a roughly 3,000 meters reverse circulation drilling program at its Greater Duchess copper gold project in Queensland, targeting extensions of high-priority mineralization at the Trekelano deposit.In addition, more assay results from a recently completed diamond drilling program are also pending, providing near-term news flow alongside the current drilling program, the equity research firm said.Leveraging its binding tolling and offtake deals with Glencore provides a low capital pathway to first production for Carnaby, and the first three years of production on Euroz Hartleys' modeling should come from lower-risk open pit reserves in the Trekelano, Mt Hope and Lady Fanny operations, it said.The equity research firm maintain a speculative buy recommendation on the stock with a price target of AU$0.96.

$ASX:CNB
Asia

South32 Posts 1% Rise in Year-to-March Alumina Production

South32 (ASX:S32) reported a 1% increase in alumina production year-to-date to March, helped by record production in its Brazil Alumina segment, according to a Wednesday filing with the Australian bourse.Aluminium production was mostly flat during the period, as its Hillside Aluminium smelter continued to evaluate its maximum technical capacity.Sierra Gorda, a Chile-based copper mine in which South32 holds a 45% stake, delivered a record quarterly distribution of $135 million to the company.South32 said its annual production guidance remained on track for all operations, apart from Australia Manganese, where the fiscal 2026 production outlook was cut by 6% to 3,000 kilo wet metric tonnes due to elevated site water levels and heavy rainfall following Tropical Cyclone Narelle.

$ASX:S32